Relay Therapeutics, Inc.
RLAY
Classifica tra le azioni
#4010
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$18.65
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$4.09B
Variazione (1 giorno)
9.15%
Variazione (1 anno)
164.96%
Paese
US
Scambia Relay Therapeutics, Inc. (RLAY)
Categoria
Healthcare
Ricavi di Relay Therapeutics, Inc. (RLAY)
Ricavi nel Jun 2026 TTM: $10.35M
Secondo gli ultimi rapporti finanziari di Relay Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $10.35M. Nel 2023, l'azienda ha registrato ricavi di $25.55M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $1.38M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Relay Therapeutics, Inc. da 2018 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $10.35M | 3.43% |
| 2024 | $10.01M | -60.83% |
| 2023 | $25.55M | 1,749.82% |
| 2022 | $1.38M | -54.41% |
| 2021 | $3.03M | -96.34% |
| 2020 | $82.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 121,873.91% |
US
|
|
| $2.23B | 21,426.57% |
US
|
|
| $15.74B | 152,019.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 58,076.69% |
NL
|
